Artwork

Content provided by MedPage Today. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MedPage Today or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

What to Know About the Factor XIa Inhibitors on the Horizon

17:53
 
Share
 

Manage episode 403459834 series 2546758
Content provided by MedPage Today. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MedPage Today or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
A novel class of antithrombotic medication, the factor XIa inhibitors, has had a rocky start but is powering through phase III trials, which are now underway. MedPage Today sat down to discuss the novel agents with Graeme Hankey, MBBS, MD, of the University of Western Australia School of Medicine & Pharmacology and Sir Charles Gairdner Hospital, both in Perth, Australia. He’s also co-chair of the Secondary Stroke Prevention Executive Committee and the Program Executive Council for the Librexia trial program for one of the factor XIa agents, milvexian. Episode produced and hosted by Crystal Phend. Sound engineering by Greg Laub.
  continue reading

55 episodes

Artwork
iconShare
 
Manage episode 403459834 series 2546758
Content provided by MedPage Today. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MedPage Today or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
A novel class of antithrombotic medication, the factor XIa inhibitors, has had a rocky start but is powering through phase III trials, which are now underway. MedPage Today sat down to discuss the novel agents with Graeme Hankey, MBBS, MD, of the University of Western Australia School of Medicine & Pharmacology and Sir Charles Gairdner Hospital, both in Perth, Australia. He’s also co-chair of the Secondary Stroke Prevention Executive Committee and the Program Executive Council for the Librexia trial program for one of the factor XIa agents, milvexian. Episode produced and hosted by Crystal Phend. Sound engineering by Greg Laub.
  continue reading

55 episodes

ทุกตอน

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide